Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
Provided By GlobeNewswire
Last update: Nov 5, 2024
– Expansion of Phase 1 CALiPSO-1 trial of CNTY-101 in autoimmune disease to include diffuse cutaneous systemic sclerosis and idiopathic inflammatory myopathy –
– Overall response rate (ORR) of 83% observed at CNTY-101 Dose Level 3B alongside a favorable safety profile in patients with r/r B-cell lymphomas in Phase 1 ELiPSE-1 study –
Read more at globenewswire.com
